Moleculin Biotech Files 2024 10-K, Details Financials
Ticker: MBRX · Form: 10-K · Filed: Mar 21, 2025 · CIK: 1659617
| Field | Detail |
|---|---|
| Company | Moleculin Biotech, Inc. (MBRX) |
| Form Type | 10-K |
| Filed Date | Mar 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, biotech, warrants
TL;DR
Moleculin Biotech's 2024 10-K is in: $1B+ assets, $896M liabilities. Warrants get adjusted for stock splits.
AI Summary
Moleculin Biotech, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, located at 5300 Memorial Drive, Suite 950, Houston, TX, reported key financial figures including $1,022 million in assets and $896 million in liabilities. The filing also details adjustments to warrant terms in case of stock splits or combinations.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Moleculin Biotech's financial health and operational status for the fiscal year 2024, including crucial details on stock-related adjustments.
Risk Assessment
Risk Level: medium — The company's financial figures, including significant liabilities, and the nature of biotech operations suggest a medium risk profile.
Key Numbers
- $1,022M — Total Assets (Represents the company's total resources as of fiscal year-end 2024.)
- $896M — Total Liabilities (Indicates the company's total obligations as of fiscal year-end 2024.)
- 2024-12-31 — Fiscal Year End (The period covered by this 10-K filing.)
- 2025-03-21 — Filing Date (The date this 10-K was officially submitted to the SEC.)
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-21 (date) — Filing date
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Company's business and mailing address
- $1,022 million (dollar_amount) — Total assets
- $896 million (dollar_amount) — Total liabilities
FAQ
What was Moleculin Biotech's net income or loss for the fiscal year ended December 31, 2024?
The provided snippet does not explicitly state the net income or loss for the fiscal year ended December 31, 2024. It focuses on balance sheet items like assets and liabilities.
What is the company's cash and cash equivalents balance as of December 31, 2024?
The filing snippet does not specify the cash and cash equivalents balance. It lists total assets as $1,022 million and total liabilities as $896 million.
How are outstanding warrants affected by stock splits or combinations?
If the Company subdivides its shares, the warrant exercise price is proportionately reduced and the number of shares under warrants is proportionately increased. Conversely, if the Company combines its shares, the warrant exercise price is proportionately increased and the number of shares under warrants is proportionately reduced.
What is Moleculin Biotech's SIC code?
Moleculin Biotech, Inc. has a Standard Industrial Classification (SIC) code of 2834, which corresponds to Pharmaceutical Preparations.
What was the total number of shares outstanding as of the filing date?
The filing snippet does not provide the total number of shares outstanding. It mentions figures related to assets, liabilities, and warrant adjustments.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 21, 2025 regarding Moleculin Biotech, Inc. (MBRX).